A vaccine for the prevention of influenza was developed during World War II in order to maintain military readiness. This was done in recognition of the high morbidity that could result among troops exposed to the virus. A similar inactivated vaccine is still in use, improved in both potency and lack of side effects. It is known to be 70 to 90 percent efficacious in healthy young adults as long as the vaccine viruses resemble those circulating. This necessitates updating the viruses in the vaccine each year. For this and other reasons, the vaccine must be given annually. Since vaccination programs must be sustained, the goal in most countries has been to reduce influenza mortality by vaccinating older individuals and those with chronic underlying diseases. An exception to this
Antiviral drugs have been available both for treatment and prophylaxis. Two of these are active only against type A viruses. A new group of drugs, acting as neuraminidase inhibitors, is active against both type A and B viruses. These drugs have been shown to have a prevention efficacy similar to vaccines. They start protecting more quickly than the vaccine, but have to be taken daily to continue protection. Therefore, vaccination will continue to be the usual means of prophylaxis. The neuraminidase inhibitors also significantly shorten the duration of illness, reducing severity and preventing complications. Influenza can be debilitating, even in the absence of complications, so that the drugs will be used for treatment during defined influenza outbreaks. They are likely also to be useful prophylactically, especially for outbreak control in nursing homes.
ARNOLD MONTO
|
|
Author Info: ARNOLD MONTO, The Gale Group Inc., Macmillan Reference USA, New York, Gale Encyclopedia of Public Health, 2002 |